Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer

Abstract

BackgroundIn the past decades, a good deal of studies has provided the possibility of the circulating microRNAs (miRNAs) as noninvasive biomarkers for cancer diagnosis. The aim of our study was to detect the levels of circulating miRNAs in tissues and plasmas of gastric cancer (GC) patients and evaluate their diagnostic value.MethodsTissue samples were collected from 85 GC patients. Plasma samples were collected from 285 GC patients and 285 matched controls. Differentially expressed miRNAs were filtered with by Agilent Human miRNA Microarray and TaqMan low density array (TLDA) with pooled samples, followed by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation. Receiver operating characteristic (ROC) curves were structured to evaluate the diagnostic accuracy of the miRNAs. The plasma level of miR-26a in GC patients of different clinical stages was compared.ResultsFour miRNAs (miR-26a, miR-142-3p, miR-148a, and miR-195) revealed coincidentally decreased levels in tissue and plasma of the GC patients compared with controls, and ROC curves were constructed to demonstrate that miR-26a had a highest area under the ROC curve (AUC) of 0.882. Furthermore, miR-26a was stably detected in the plasma of GC patients with different clinical characteristics.ConclusionPlasma miR-26a may provide a novel and stable marker of gastric cancer.

Long non‐coding RNA 00312 regulated by HOXA5 inhibits tumour proliferation and promotes apoptosis in Non‐small cell lung cancer

“…. Prior studies have noted the importance of detecting circulating miRNAs in the plasma of gastric cancer , oesophageal squamous cell carcinoma , hepatocellular carcinoma and lung cancer . Nevertheless, little is known about circulating lncRNAs in NSCLC.…”

Plasma microRNA‐based signatures to predict 3‐year postoperative recurrence risk for stage II and III gastric cancer

“…22 miR-148a can suppress tumor proliferation, invasion and metastasis in gastric cancer by regulating several target genes and pathways. 30 In a large profile study of GC, miR-125b was one of the three most important miRNAs involved in the progression-related signature. 26 miR-126, miR-125b and miR-26a were involved in the pathogenesis of many cancers by different mechanisms, acting as oncogenes or tumor suppressor genes.…”

“…27,28 In GC, miR-26a suppressed GC growth and metastasis by targeting FGF9, 29 and circulating miR-26a in plasma was a potential marker for diagnosis in GC. 30 In a large profile study of GC, miR-125b was one of the three most important miRNAs involved in the progression-related signature. 31 In the field of functional research, there have been controversies about miR-126 32,33 and miR-125b [34][35][36] in GC, suggesting that they might be expressed in a tissue-specific pattern and have cell content-dependent functions.…”

The role of extracellular vesicle microRNAs in cancer biology

“…Several studies have shown that exosomal miRNAs can be detected in a variety of body fluids, from blood to breast milk, and that their levels are correlated with patient status [4,5,[60][61][62][63][64][65][66][67][68][69][70][71][72][73] (Table 1). On January 21, 2016, cancer diagnosis using exosomes from blood became commercially available in the US (http://www.exosomedx.com) [6].…”